Edgewise Therapeutics Inc
EWTXHealthcare|Biotechnology|USA
$45.41
-2.94 (-6.08%)
Tangible Book
$4.59
Earnings Power
$4.34
About
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
Stock Price
+227.4%(1Y)
Pipeline Summary
18 total trials11
Phase 1
5
Phase 2
0
Phase 3
0
Phase 4
Completed: 9Active: 5ENROLLING_BY_INVITATION: 1NOT_YET_RECRUITING: 1Recruiting: 2
Active Trials (7)
Defining Endpoints in Becker Muscular Dystrophy
NCT05257473Becker Muscular Dystrophy
Active
Enrollment: 80 participants
A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)
NCT06347159Hypertrophic Cardiomyopathy
Phase 2Active
Enrollment: 100 participants
Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)
NCT05291091Becker Muscular Dystrophy
Phase 2Active
Enrollment: 244 participants
A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)
NCT05540860Duchenne Muscular Dystrophy
Phase 2Active
Enrollment: 76 participants
Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy
NCT06100887Duchenne Muscular Dystrophy
Phase 2Active
Enrollment: 43 participants
BioScore
5.3/10
Watchlist
Ownership
Recent Insider Trades
Russell Alan JSELL
2026-07-01200,000 shares @ $39.41
Donovan Joanne M.SELL
2026-05-0555,230 shares @ $37.88
Donovan Joanne M.SELL
2026-04-0128,662 shares @ $32.31
Donovan Joanne M.SELL
2026-03-3121,338 shares @ $32.12
Donovan Joanne M.SELL
2026-03-2716,358 shares @ $30.98
Recent News
2026-07-09 14:08:14
2026-07-06 15:50:25
2026-07-01 13:00:34
2026-06-17 15:35:43
2026-06-17 13:00:31
Data last updated: Jul 13, 2026, 12:40 PM